Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV_IMPACT maternal RSV vaccine trial
PACTR202504593185463Phase 3Recruiting
- Sponsor
- Wits Health Consortium
- Start
- May 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Abrysvo with Placebo (2 arms). Started May 2025; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on PACTR202504593185463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504593185463.